Research and Development

Showing 15 posts of 9594 posts found.

gilead-sciences

Gilead’s PrEP drug Descovy should be approved for men and transgender women but not cis-gender women, FDA advisory panel says

August 8, 2019 Research and Development AIDS, Gilead, HIV, PrEP, descovy, pharma

Independent experts on a panel advising the FDA have voted in favour of Gilead’s new PrEP drug Descovy in men …

Rhythm Pharma’s obesity drug shows positive results in two Phase 3 trials

August 8, 2019 Research and Development Rhythm pharma, clinical trial, health, obesity, pharma

Rhythm Pharma’s obesity drug setmelanotide achieved positive results in two pivotal Phase 3 trials. In both studies, setmelanotide met its …
dupixentpackage

Sanofi’s Dupixent improves skin clearance in paediatric atopic dermatitis

August 7, 2019 Research and Development Dupixent, Sanofi, atopic dermatitis, pharma

As the therapy secured approval in Europe for treatment of adolescent patients with moderate-to-severe atopic dermatitis, Sanofi has revealed new …
astrazeneca_plaque

AstraZeneca’s Lynparza meets primary endpoint in Phase 3 prostate cancer trial

August 7, 2019 Research and Development Lynpraza, PARP inhibitor, lynparza, pharma, prostate cancer

AstraZeneca’s PARP inhibitor Lynparza was successful in improving progression free survival in a Phase 3 trial of patients with metastatic …

NICE recommends Pierre Fabre’s Nerlynx in adjuvant HER2+ breast cancer

August 7, 2019 Research and Development, Sales and Marketing Cancer, NCIE, NHS, Nerlynx, Pierre Fabre, UK, breast cancer

Pierre Fabre’s Nerlynx (neratinib) has been recommended by NICE as a new option for NHS patients with early hormone-receptor-positive, human …
medicinal_cannabis_uk_review

Medicinal cannabis company Spectrum makes first shipment into UK

August 7, 2019 Research and Development Spectrum, UK, cannabis, medicinalcannabis, pharma

Medicinal cannabis company Spectrum Europe has made its first shipment of cannabis into the UK, making it one of the …
novartis_window

Novartis hid faulty data from FDA over $2.1 million gene therapy Zolgensma

August 7, 2019 Research and Development AveXis, FDA, Novartis, Zolgensma, gene therapy, pharma

Novartis hid faulty data from the FDA until their drug was approved, according to a statement from Dr Peter Marks, …
troy_robinson

Troy Robinson promoted to managing director of Chugai Pharma Europe

August 6, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Troy Robinson has been taken on as the new managing director of Chugai Pharma Europe. Mike Crosher will succeed him …
lilly_building_with_american_flag_web

Lilly’s Emgality smashes all Phase 3 endpoints in migraine sub-population

August 6, 2019 Manufacturing and Production, Research and Development Eli Lilly, Emgality, migraine, pharma

New Phase 3 data have been revealed on Eli Lilly’s Emgality (galcanezumab-gnlm), detailing its success in meeting all of its …
vaila_morrison

Living with a rare genetic neurodevelopmental disorder

August 5, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing KAT6A, feature, patient experience, pharma, rare disease

Vaila Morrison’s daughter Eilidh was born with the ultra-rare condition KAT6A. As a designer and architect by profession, Vaila told …
headquarters_ingelheim3

Additional data for Boehringer’s Giotrif combo shows strong overall survival benefit in lung cancer sub-population

August 5, 2019 Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, giotrif, lung cancer, pharma

German firm Boehringer Ingelheim has released new interim data from a real-world evidence study investigating the efficacy of Giotrif/Gilotrif (afatinib) …

Pollen spores could be used to protect potent, ocean-dwelling antibiotics in fighting antibiotic resistant superbugs

August 5, 2019 Research and Development, Sales and Marketing AMR, Antibiotics, MRSA, club moss, pharma, pollen, spores

Spores from a plant called the common club moss (Lycopodium clavatum) could be used to protect light-sensitive antibiotics, that are …
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

August 2, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Pfizer dominated the headlines this week as the US firm closed its $9.8 billion merger with GSK and announced that …
novartis_outside_1

Novartis’ Kisqali reinforces overall survival benefit in postmenopausal HR+/HER2- breast cancer

August 1, 2019 Research and Development Cancer, Kisqali, Novartis, breast cancer, pharma

New Phase 3 evidence has emerged on the efficacy of Novartis’ Kisqali (ribociclib) in combination with AstraZeneca’s Faslodex (fulvestrant) in …
The Gateway to Local Adoption Series

Latest content